Skip to Content

Zylet Approval History

FDA Approved: Yes (First approved December 14, 2004)
Brand name: Zylet
Generic name: loteprednol and tobramycin
Dosage form: Ophthalmic Suspension
Company: Bausch & Lomb
Treatment for: Uveitis, Iritis, Conjunctivitis, Bacterial, Keratitis, Cyclitis

Zylet (loteprednol etabonate and tobramycin ophthalmic suspension) a topical anti-inflammatory corticosteroid and antibiotic combination for use in the treatment of inflammatory ocular conditions.

Development History and FDA Approval Process for Zylet

DateArticle
Dec 14, 2004Approval Zylet Bausch & Lomb - Treatment for Inflammatory Ocular Conditions
Aug  9, 2004FDA Issues Approvable Letter to Bausch & Lomb for Ophthalmic Anti-inflammatory/Antibiotic Combination Product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide